1
|
Production of nanostructured systems: Main and innovative techniques. Drug Discov Today 2023; 28:103454. [PMID: 36402265 DOI: 10.1016/j.drudis.2022.103454] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2022] [Revised: 09/24/2022] [Accepted: 11/11/2022] [Indexed: 11/18/2022]
Abstract
In the constant search for the development of more-specific and more-selective drugs, especially with regard to the challenge of encapsulating hydrophilic molecules, polymer nanotechnologies are remarkable for their biocompatible and biodegradable properties. The most-used nanoencapsulation methods consist of emulsification procedures, where emulsified droplets of a given polymer and drug solidify into nanoparticles after solvent extraction from the polymeric phase. This review introduces conventional emulsification methods but also highlights new emulsification technologies such as microfluidics, membrane emulsification and other techniques, including spray drying, inkjet printing and electrospraying.
Collapse
|
2
|
Impact of excipient choice on the aerodynamic performance of inhalable spray-freeze-dried powders. Int J Pharm 2020; 586:119564. [DOI: 10.1016/j.ijpharm.2020.119564] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Revised: 06/17/2020] [Accepted: 06/18/2020] [Indexed: 11/21/2022]
|
3
|
Ramazani F, Chen W, van Nostrum CF, Storm G, Kiessling F, Lammers T, Hennink WE, Kok RJ. Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: State-of-the-art and challenges. Int J Pharm 2016; 499:358-367. [DOI: 10.1016/j.ijpharm.2016.01.020] [Citation(s) in RCA: 162] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Revised: 01/08/2016] [Accepted: 01/09/2016] [Indexed: 11/27/2022]
|
4
|
Ramazani F, Hiemstra C, Steendam R, Kazazi-Hyseni F, Van Nostrum C, Storm G, Kiessling F, Lammers T, Hennink W, Kok R. Sunitinib microspheres based on [PDLLA-PEG-PDLLA]-b-PLLA multi-block copolymers for ocular drug delivery. Eur J Pharm Biopharm 2015; 95:368-77. [DOI: 10.1016/j.ejpb.2015.02.011] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2014] [Revised: 02/05/2015] [Accepted: 02/09/2015] [Indexed: 10/24/2022]
|
5
|
Li H, Wan H, Xia T, Chen M, Zhang Y, Luo X, Li X. Therapeutic angiogenesis in ischemic muscles after local injection of fragmented fibers with loaded traditional Chinese medicine. NANOSCALE 2015; 7:13075-13087. [PMID: 26176198 DOI: 10.1039/c5nr02005k] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Therapeutic angiogenesis remains the most effective method to re-establish a proper blood flow in ischemic tissues. There is a great clinical need to identify an injectable format to achieve a well accumulation following local administration and a sustained delivery of biological factors at the ischemic sites. In the current study, fragmented nanofibers with loaded traditional Chinese medicines, astragaloside IV (AT), the main active ingredient of astragalus, and ferulic acid (FA), the main ingredient of angelica, were proposed to promote the microvessel formation after intramuscular injection into ischemic hindlimbs. Fragmented fibers with average lengths of 5 (FF-5), 20 (FF-20) and 80 μm (FF-80) were constructed by the cryocutting of aligned electrospun fibers. Their dispersion in sodium alginate solution (0.2%) indicated good injectability. After injection into the quadriceps muscles of the hindlimbs, FF-20 and FF-80 fiber fragments showed higher tissue retentions than FF-5, and around 90% of the injected doses were determined after 7 days. On a hindlimb ischemia model established by ligating the femoral arteries, intramuscular injection of the mixtures of FA-loaded and AT-loaded FF-20 fiber fragments substantially reduced the muscle degeneration with minimal fibrosis formation, significantly enhanced the neovessel formation and hindlimb perfusion in the ischemic tissues, and efficiently promoted the limb salvage with few limb losses. Along with the easy manipulation and lower invasiveness for in vivo administration, fragmented fibers should become potential drug carriers for disease treatment, wound recovery and tissue repair after local injection.
Collapse
Affiliation(s)
- Huiyan Li
- Key Laboratory of Advanced Technologies of Materials, Ministry of Education of China, School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu 610031, P. R. China.
| | | | | | | | | | | | | |
Collapse
|
6
|
Wanning S, Süverkrüp R, Lamprecht A. Pharmaceutical spray freeze drying. Int J Pharm 2015; 488:136-53. [PMID: 25900097 DOI: 10.1016/j.ijpharm.2015.04.053] [Citation(s) in RCA: 120] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Revised: 04/15/2015] [Accepted: 04/16/2015] [Indexed: 11/29/2022]
Abstract
Pharmaceutical spray-freeze drying (SFD) includes a heterogeneous set of technologies with primary applications in apparent solubility enhancement, pulmonary drug delivery, intradermal ballistic administration and delivery of vaccines to the nasal mucosa. The methods comprise of three steps: droplet generation, freezing and sublimation drying, which can be matched to the requirements given by the dosage form and route of administration. The objectives, various methods and physicochemical and pharmacological outcomes have been reviewed with a scope including related fields of science and technology.
Collapse
Affiliation(s)
- Stefan Wanning
- Laboratory of Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy, University of Bonn, Bonn, Germany
| | - Richard Süverkrüp
- Laboratory of Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy, University of Bonn, Bonn, Germany
| | - Alf Lamprecht
- Laboratory of Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy, University of Bonn, Bonn, Germany; Laboratory of Pharmaceutical Engineering (EA4267), University of Franche-Comté, Besançon, France.
| |
Collapse
|
7
|
George EM, Liu H, Robinson GG, Mahdi F, Perkins E, Bidwell GL. Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis. Vasc Cell 2015; 7:1. [PMID: 25653833 PMCID: PMC4316602 DOI: 10.1186/s13221-014-0026-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Accepted: 12/16/2014] [Indexed: 12/22/2022] Open
Abstract
Background Therapeutic angiogenesis with vascular endothelial growth factor (VEGF), delivered either via recombinant protein infusion or via gene therapy, has shown promise in preclinical models of various diseases including myocardial infarction, renovascular disease, preeclampsia, and neurodegenerative disorders. However, dosing, duration of expression, and tissue specificity are challenges to VEGF gene therapy, and recombinant VEGF delivery suffers from extremely rapid plasma clearance, necessitating continuous infusion and/or direct injection at the site of interest. Methods Here we describe a novel growth factor purification and delivery system (PADS) generated by fusion of VEGF121 to a protein polymer based on Elastin-like Polypeptide (ELP). ELP is a thermally responsive biopolymer derived from a five amino acid repeat sequence found in human tropoelastin. VEGFPADS were constructed by fusion of the ELP coding sequence in-frame with the VEGF121 coding sequence connected by a flexible di-glycine linker. In vitro activity of VEGFPADS was determined using cell proliferation, tube formation, and migration assays with vascular endothelial cells. Pharmacokinetics and biodistribution of VEGFPADS in vivo were compared to free VEGF in mice using quantitative fluorescence techniques. Results ELP fusion allowed for recombinant expression and simple, non-chromatographic purification of the ELP-VEGF121 chimera in yields as high as 90 mg/L of culture and at very high purity. ELP fusion had no effect on the VEGF activity, as the VEGFPADS were equally potent as free VEGF121 in stimulating HUVEC proliferation, tube formation, and migration. Additionally, the VEGFPADS had a molecular weight five-fold larger than free VEGF121, which lead to slower plasma clearance and an altered biodistribution after systemic delivery in vivo. Conclusion PADS represent a new method of both purification and in vivo stabilization of recombinant growth factors. The use of this system could permit recombinant growth factors to become viable options for therapeutic angiogenesis in a number of disease models. Electronic supplementary material The online version of this article (doi:10.1186/s13221-014-0026-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Eric M George
- Department of Physiology and Biophysics, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216 USA ; Department of Biochemistry, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216 USA
| | - Huiling Liu
- Department of Neurology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216 USA
| | - Grant G Robinson
- Department of Neurology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216 USA
| | - Fakhri Mahdi
- Department of Neurology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216 USA
| | - Eddie Perkins
- Department of Neurosurgery, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216 USA ; Department of Neurobiology and Anatomical Sciences, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216 USA
| | - Gene L Bidwell
- Department of Biochemistry, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216 USA ; Department of Neurology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216 USA
| |
Collapse
|
8
|
Klueh U, Antar O, Qiao Y, Kreutzer DL. Role of vascular networks in extending glucose sensor function: Impact of angiogenesis and lymphangiogenesis on continuous glucose monitoring in vivo. J Biomed Mater Res A 2014; 102:3512-22. [PMID: 24243850 PMCID: PMC4012020 DOI: 10.1002/jbm.a.35031] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2013] [Revised: 10/22/2013] [Accepted: 10/31/2013] [Indexed: 01/10/2023]
Abstract
The concept of increased blood vessel (BV) density proximal to glucose sensors implanted in the interstitial tissue increases the accuracy and lifespan of sensors is accepted, despite limited existing experimental data. Interestingly, there is no previous data or even conjecture in the literature on the role of lymphatic vessels (LV) alone, or in combination with BV, in enhancing continuous glucose monitoring (CGM) in vivo. To investigate the impact of inducing vascular networks (BV and LV) at sites of glucose sensor implantation, we utilized adenovirus based local gene therapy of vascular endothelial cell growth factor-A (VEGF-A) to induce vessels at sensor implantation sites. The results of these studies demonstrated that (1) VEGF-A based local gene therapy increases vascular networks (blood vessels and lymphatic vessels) at sites of glucose sensor implantation; and (2) this local increase of vascular networks enhances glucose sensor function in vivo from 7 days to greater than 28 days postsensor implantation. This data provides "proof of concept" for the effective usage of local angiogenic factor (AF) gene therapy in mammalian models in an effort to extend CGM in vivo. It also supports the practice of a variety of viral and nonviral vectors as well as gene products (e.g. anti-inflammatory and anti-fibrosis genes) to engineer "implant friendly tissues" for the usage with implantable glucose sensors as well as other implantable devices.
Collapse
Affiliation(s)
- Ulrike Klueh
- Center for Molecular Tissue Engineering, University of Connecticut, School of Medicine, Farmington, Connecticut 06030
- Department of Surgery, University of Connecticut, School of Medicine, Farmington, Connecticut 06030
| | - Omar Antar
- Center for Molecular Tissue Engineering, University of Connecticut, School of Medicine, Farmington, Connecticut 06030
- Department of Surgery, University of Connecticut, School of Medicine, Farmington, Connecticut 06030
| | - Yi Qiao
- Center for Molecular Tissue Engineering, University of Connecticut, School of Medicine, Farmington, Connecticut 06030
- Department of Surgery, University of Connecticut, School of Medicine, Farmington, Connecticut 06030
| | - Donald L. Kreutzer
- Center for Molecular Tissue Engineering, University of Connecticut, School of Medicine, Farmington, Connecticut 06030
- Department of Surgery, University of Connecticut, School of Medicine, Farmington, Connecticut 06030
| |
Collapse
|
9
|
Pokholenko IO, Chetyrkina MD, Dubey LV, Dubey IY, Moshynets OV, Sheludko EV, Shpylova SP, Degtiarova MI, Kordium VA. Development and characterization of porous functionalized collagen scaffolds for delivery of FGF-2. ACTA ACUST UNITED AC 2014. [DOI: 10.7124/bc.000899] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
| | - M. D. Chetyrkina
- В«Institute of BiologyВ», Taras Shevchenko National University of Kyiv
| | - L. V. Dubey
- Institute of Molecular Biology and Genetics, NAS of Ukraine
| | - I. Ya. Dubey
- Institute of Molecular Biology and Genetics, NAS of Ukraine
| | | | - E. V. Sheludko
- Institute of Bioorganic Chemistry and Petrochemistry, NAS of Ukraine
| | - S. P. Shpylova
- Institute of Molecular Biology and Genetics, NAS of Ukraine
| | - M. I. Degtiarova
- В«Institute of BiologyВ», Taras Shevchenko National University of Kyiv
| | - V. A. Kordium
- Institute of Molecular Biology and Genetics, NAS of Ukraine
| |
Collapse
|
10
|
Schweizer D, Vostiar I, Heier A, Serno T, Schoenhammer K, Jahn M, Jones S, Piequet A, Beerli C, Gram H, Goepferich A. Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation. J Control Release 2013; 172:975-82. [PMID: 24140353 DOI: 10.1016/j.jconrel.2013.10.010] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2013] [Revised: 10/06/2013] [Accepted: 10/07/2013] [Indexed: 02/08/2023]
Abstract
The sustained and localized delivery of monoclonal antibodies has become highly relevant, because of the increasing number of investigated local delivery applications in recent years. As the local delivery of antibodies is associated with high technological hurdles, very few successful approaches have been reported in the literature so far. Alginate-based delivery systems were previously described as promising sustained release formulations for monoclonal antibodies (mAbs). In order to further investigate their applicability, a single-dose animal study was conducted to compare the biocompatibility, the pharmacokinetics and the bioavailability of a human monoclonal antibody liquid formulation with two alginate-based sustained delivery systems after subcutaneous administration in rats. 28 days after injection, the depot systems were still found in the subcutis of the animals. A calcium cross-linked alginate formulation, which was injected as a hydrogel, was present as multiple compartments separated by subcutaneous tissue. An in situ forming alginate formulation was recovered as a single compact and cohesive structure. It can be assumed that the multiple compartments of the hydrogel formulation led to almost identical pharmacokinetic profiles for all tested animals, whereas the compact nature of the in situ forming system resulted in large interindividual variations in pharmacokinetics. As compared to the liquid formulation the hydrogel formulations led to lower mAb serum levels, and the in situ forming system to a shift in the time to reach the maximum mAb serum concentration (Tmax) from 2 to 4 days. Importantly, it was shown that after 28 days only marginal amounts of residual mAb were present in the alginate matrix and in the tissue at the injection site indicating nearly complete release. In line with this finding, systemic drug bioavailability was not affected by using the controlled release systems. This study successfully demonstrates the suitability and underlines the potential of polyanionic systems for local and controlled mAb delivery.
Collapse
Affiliation(s)
- Daniel Schweizer
- Novartis Pharma AG, Biologics Process Research & Development, 4002 Basel, Switzerland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Bai Y, Yin G, Huang Z, Liao X, Chen X, Yao Y, Pu X. Localized delivery of growth factors for angiogenesis and bone formation in tissue engineering. Int Immunopharmacol 2013; 16:214-23. [PMID: 23587487 DOI: 10.1016/j.intimp.2013.04.001] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2013] [Revised: 04/01/2013] [Accepted: 04/01/2013] [Indexed: 01/14/2023]
Abstract
Angiogenesis is a key component of bone formation. Delivery of growth factors for both angiogenesis and osteogenesis is about to gain important potential as a future therapeutic tool. This review focuses on these growth factors that have dual functions in angiogenesis and osteogenesis, and their localized application. A major hurdle in the clinical development of growth factor therapy so far is how to assure safe and efficacious therapeutic use of such factors and avoid unwanted side effects and toxicity. It is now firmly established from the available information that the type, dose, combinations and delivery kinetics of growth factors all play a decisive role for the success of growth factor therapy. All of these parameters have to be adapted and optimized for each animal model or clinical case. In this review we discuss some important parameters associated with growth factor therapy and present an overview of selected preclinical studies, followed by a conceptual description of both established and proposed delivery strategies meeting therapeutic needs.
Collapse
Affiliation(s)
- Yan Bai
- College of Materials Science and Engineering, Sichuan University, Chengdu 610064, PR China
| | | | | | | | | | | | | |
Collapse
|
12
|
Simón-Yarza T, Formiga FR, Tamayo E, Pelacho B, Prosper F, Blanco-Prieto MJ. Vascular endothelial growth factor-delivery systems for cardiac repair: an overview. Am J Cancer Res 2012; 2:541-52. [PMID: 22737191 PMCID: PMC3381347 DOI: 10.7150/thno.3682] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2011] [Accepted: 12/23/2011] [Indexed: 11/05/2022] Open
Abstract
Since the discovery of the Vascular Endothelial Growth Factor (VEGF) and its leading role in the angiogenic process, this has been seen as a promising molecule for promoting neovascularization in the infarcted heart. However, even though several clinical trials were initiated, no therapeutic effects were observed, due in part to the short half life of this factor when administered directly to the tissue. In this context, drug delivery systems appear to offer a promising strategy to overcome limitations in clinical trials of VEGF.The aim of this paper is to review the principal drug delivery systems that have been developed to administer VEGF in cardiovascular disease. Studies published in the last 5 years are reviewed and the main features of these systems are explained. The tissue engineering concept is introduced as a therapeutic alternative that holds promise for the near future.
Collapse
|
13
|
Musilli C, Karam JP, Paccosi S, Muscari C, Mugelli A, Montero-Menei CN, Parenti A. Pharmacologically active microcarriers for endothelial progenitor cell support and survival. Eur J Pharm Biopharm 2012; 81:609-16. [PMID: 22561954 DOI: 10.1016/j.ejpb.2012.04.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2011] [Revised: 04/13/2012] [Accepted: 04/18/2012] [Indexed: 12/29/2022]
Abstract
The regenerative potential of endothelial progenitor cell (EPC)-based therapies is limited due to poor cell viability and minimal retention following application. Neovascularization can be improved by means of scaffolds supporting EPCs. The aim of the present study was to investigate whether human early EPCs (eEPCs) could be efficiently cultured on pharmacologically active microcarriers (PAMs), made with poly(d,l-lactic-coglycolic acid) and coated with adhesion/extracellular matrix molecules. They may serve as a support for stem cells and may be used as cell carriers providing a controlled delivery of active protein such as the angiogenic factor, vascular endothelial growth factor-A (VEGF-A). eEPC adhesion to fibronectin-coated PAMs (FN-PAMs) was assessed by means of microscopic evaluation and by means of Alamar blue assay. Phospho ERK(1/2) and PARP-1 expression was measured by means of Western blot to assess the survival effects of FN-PAMs releasing VEGF-A (FN-VEGF-PAMs). The Alamar blue assay or a modified Boyden chamber assay was employed to assess proliferative or migratory capacity, respectively. Our data indicate that eEPCs were able to adhere to empty FN-PAMs within a few hours. FN-VEGF-PAMs increased the ability of eEPCs to adhere to them and strongly supported endothelial-like phenotype and cell survival. Moreover, the release of VEGF-A by FN-PAMs stimulated in vitro HUVEC migration and proliferation. These data strongly support the use of PAMs for supporting eEPC growth and survival and for stimulating resident mature human endothelial cells.
Collapse
Affiliation(s)
- Claudia Musilli
- Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy
| | | | | | | | | | | | | |
Collapse
|